Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO guidelines committee. Ann Oncol. 2020;31:1435–48.

Article  CAS  PubMed  Google Scholar 

Switzer B, Puzanov I, Skitzki JJ, Hamad L, Ernstoff MS. Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract. 2022;18:335–51.

Article  PubMed  PubMed Central  Google Scholar 

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409–36.

Article  PubMed  Google Scholar 

Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J Clin Med. 2020;9:223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahni S, Valecha G, Sahni A. Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy. Cureus. 2018;10: e3700.

PubMed  PubMed Central  Google Scholar 

Xu Y, Wan B, Chen X, Zhan P, Zhao Y, Zhang T, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8:413–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greil R, Hutterer E, Hartmann TN, Pleyer L. Reactivation of dormant anti-tumor immunity—a clinical perspective of therapeutic immune checkpoint modulation. Cell Commun Signal. 2017;15:5.

Article  PubMed  PubMed Central  Google Scholar 

Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126:1663–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene. 1999;18:7740–7.

Article  CAS  PubMed  Google Scholar 

Wang B, Niu D, Lai L, Ren EC. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun. 2013;4:2359.

Article  PubMed  Google Scholar 

Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, et al. Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment. Cancer Res. 2021;81:3079–91.

Article  CAS  PubMed  Google Scholar 

Slatter TL, Wilson M, Tang C, Campbell HG, Ward VK, Young VL, et al. Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. Oncoimmunology. 2016;5: e1112941.

Article  PubMed  Google Scholar 

Pandya P, Kublo L, Stewart-Ornstein J. p53 promotes cytokine expression in melanoma to regulate drug resistance and migration. Cells. 2022;11:405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, et al. Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity. Cancer Discov. 2021;11:3090–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4:5011–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020. https://doi.org/10.1242/jcs.237453.

Article  PubMed  Google Scholar 

Haronikova L, Bonczek O, Zatloukalova P, Kokas-Zavadil F, Kucerikova M, Coates PJ, et al. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? Cell Mol Biol Lett. 2021;26:53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, et al. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J Clin Invest. 2022;132: e148141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahin I, Zhang S, Navaraj A, Zhou L, Dizon D, Safran H, et al. AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discov. 2020;6:57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li R, Zatloukalova P, Muller P, Gil-Mir M, Kote S, Wilkinson S, et al. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cell Mol Biol Lett. 2020;25:41.

Article  PubMed  PubMed Central  Google Scholar 

Tojyo I, Shintani Y, Nakanishi T, Okamoto K, Hiraishi Y, Fujita S, et al. PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma. Maxillofac Plast Reconstr Surg. 2019;41:56.

Article  PubMed  PubMed Central  Google Scholar 

Sun H, Liu S-Y, Zhou J-Y, Xu J-T, Zhang H-K, Yan H-H, et al. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine. 2020;60: 102990.

Article  PubMed  PubMed Central  Google Scholar 

Alos L, Fuster C, Castillo P, Jares P, Garcia-Herrera A, Marginet M, et al. TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. Ann Transl Med. 2020;8:1218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu X-Y, Zhang X-W, Wang F, Lin Y-B, Wang W-D, Chen Y-Q, et al. Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis. 2018;10:1891–902.

Article